ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Polymerase Theta Helicase Inhibitor AZD4956

Its studies are led by AstraZeneca.

Furthest: phase 2, since Feb 26, 20261 company-led study, 1 open or runningNext primary completion: Mar 29, 2030 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca11 open or runningphase 2since Feb 26, 2026Feb 26, 2026Mar 29, 2030phase 2 · NCT07446855
  • Named in AstraZeneca’s own pipeline as AZD4956, phase 1, as of Oct 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 26, 2026First study: phase 2 study in Solid TumoursFirst studyNCT07446855 · 180 planned · United States, Australia, Japan and more

Ahead

  1. Mar 29, 2030Primary completion: phase 2 study in Solid TumoursNCT07446855

TargetBeta

“An orally bioavailable inhibitor of DNA polymerase (pol) theta helicase, with potential antineoplastic activity. Upon oral administration, DNA polymerase theta inhibitor AZD4956 specifically targets, binds to and inhibits the pol theta helicase domain and thereby inhibits the activity of pol thet…”NCIt, read by Claude

Other programs on POLQ

ProgramCompanyFurthest phaseStudies
SYN818rulehangzhou-synrx-therapeutics-biomedical-technology-co-ltdphase 12

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07446855Solid Tumours · United States, Australia, Japan and more2RecruitingMar 29, 2030180

How it is read

Names in the registry

  • “AZD4956”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.